Conexeu Sciences Inc(CNXU) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 6:22 PM ET (Korea 10/30 07:22)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.54 | Insider Own | 60.17% | Shs Outstand | 27.4M | Perf Week | -14.24% |
| Market Cap | 0.09B | Forward P/E | - | EPS next Y | - | Insider Trans | 2.22% | Shs Float | 11.2M | Perf Month | -20.73% |
| Enterprise Value | 0.09B | PEG | - | EPS next Q | - | Inst Own | 7.59% | Short Float | 2.64% | Perf Quarter | -65.94% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 92.2% | Short Ratio | 1.1 | Perf Half Y | - |
| Sales | 0.00B | P/B | 13.25 | EPS next 5Y | - | ROA | - | Short Interest | 0.30M | Perf YTD | -79.04% |
| Book/sh | 0.21 | P/C | 39.48 | EPS past 3/5Y | -950.49% - | ROE | - | 52W High | -84.94% ($18.79) | Perf Year | - |
| Cash/sh | 0.07 | P/FCF | - | Sales past 3/5Y | - | ROIC | -231.59% | 52W Low | 1.8% ($2.78) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 7.94% 14.25% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.46 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.31 | EPS Q/Q | -1549.12% | Profit Margin | - | RSI (14) | 37.02 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.31 | Sales Q/Q | - | SMA20 | -14.51% ($3.31) | Beta | - | Target Price | $20 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/07/01 | SMA50 | -37.82% ($4.55) | Rel Volume | 1.53 | Prev Close | $2.88 |
| Employees | 4 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | - | SMA200 | -64.55% ($7.98) | Avg Volume(3M) | 0.27M | Price | $2.83 |
| IPO | 2026/5/21 | Option/Short | No/Yes | Trades | 1632 | Volume | 413,953 | Change | -1.74% |
🧬 Connexios Sciences (CNXU) is a U.S. clinical-stage biotechnology company that develops bio-regenerative scaffolds for wound healing, dental tissue regeneration, and cosmetic/aesthetic applications, based on its proprietary extracellular matrix platform technology.
Over the past 1 year, on the lower side
85% below its 1-year high.
Traded more than usual. That is 153% of its average volume.
CNXU has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 7.6%.
Tap to view numbers
It ranks #374 of 594 in the industry
Based on market cap of $87M.
EQ#372 Equillium Inc $90M PER - 
NTHI#373 NeOnc Technologies Holdings Inc $90M PER - CNXU#374 Conexeu Sciences Inc $87M PER - 
ATRA#375 Atara Biotherapeutics Inc $86M PER - 
CLLS#376 Cellectis ADR $85M PER - 
FAQ
What kind of company is CNXU?
CNXU belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CNXU?
The market cap of CNXU is approximately $87M, ranking 4,556 within its sector.
What is the 52-week high and low for CNXU?
CNXU has recorded a 52-week high of $18.79 and a low of $2.78.
